Two novel truncating variants of the AAAS gene causative of the triple A syndrome by V. Vezzoli et al.
1 
 
 
Two novel truncating variants of the AAAS gene causative of the Triple A Syndrome  
 
Valeria Vezzoli1*, Paolo Duminuco1*, Gabriele Pogliaghi1, Maria Saccone1, Biagio Cangiano1,3, Maria Cri-
stina Rosatelli2, Antonella Meloni2, Luca Persani1,3, Marco Bonomi1,3  
 
* These authors contribute equally to this work 
1 IRCCS Istituto Auxologico Italiano, Division of Endocrine and Metabolic Diseases and Lab. of Endocrine 
and Metabolic Research, Milan, Italy; 2 Pediatric Hospital “Microcitemico” Antonio Cao, Azienda Ospedali-
era Brotzu, University of Cagliari, Cagliary, Italy; 3 Department of Clinical Sciences and Community Health, 
University of Milan, Milan, Italy;  
Corresponding author:  
Marco Bonomi, MD  
Dipartimento di Scienze Cliniche e di Comunità - Università degli studi di Milano 
IRCCS Istituto Auxologico Italiano - Dipartimento di Medicina Endocrino-Metabolica 
Piazzale Brescia 20 
20149 Milano 
Phone: +39-02619112390 
Fax: +39-02619113033 
email: marco.bonomi@unimi.it 
 
Short Title: AAAS gene truncating variants causative of Triple A syndrome 
Key words: ALADIN protein, Triple A syndrome, Congenital Hypoadrenalism, Human Splicing Finder, 
mRNA splicing, Allgrove syndrome 
Funding and Acknowledgements 
This work was supported by funds from IRCCS Istituto Auxologico Italiano (Ricerca Corrente Funds: 
05C822). Authors are in debt with Professor Sungjoo Kim Yoon (Catholic University of Korea) for provid-
ing them Plasmid pEGFP-C1. 
2 
 
 
Abstract 
Purpose: The Triple-A syndrome (AAAS) is an inherited condition associated with mutations in the AAAS 
gene, which encodes a protein of 546 amino acids known as ALADIN (ALacrima Achalasia aDrenal Insuffi-
ciency Neurologic disorder) whose function is not well understood. This protein belongs to the WD-repeat 
family of regulatory proteins and is located in the nuclear pore complexes. Only a few cohorts of AAAS pa-
tients have been reported and fully characterized. Thus, the objective of the present study was to report on a 
mini-cohort of Italian AAAS patients and to get insights on their predisposing genetic defects.  
Methods: Genetic analysis of AAAS gene in Triple-A syndrome patient and molecular and functional charac-
terization of the novel identified allelic variants. 
Results: Here we describe three newly diagnosed cases of AAAS, in whom genetic analysis allowed us to 
identify two novel allelic variants in the AAAS gene: the frameshift substitution c.765 dupT (p.Gly256Trp 
fsX67) in exon 8 and the splice-site mutation in intron 11(c.997-2 A>G, IVS11-2A>G). Both variants result 
in a truncated non-functional protein, as we demonstrate by transcript analysis and expression studies.  
Conclusions: Our findings establish a pathogenic role for both new variants. Moreover, our data highlight the 
essential role of the C terminal domain of the protein for its correct targeting and function and underline the 
importance of sequencing splice sites surrounding the intron-exon junctions to ensure accurate molecular di-
agnosis and correct genetic counseling in AAAS patients. 
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1. Introduction 
Triple-A syndrome (AAAS, MIM #231550), also known as Allgrove Syndrome, is an inherited condition 
characterized by the clinical triad of adrenal insufficiency, achalasia, and alacrima [1]. It is also sporadically 
associated with variable and progressive neurological deficiency involving the central, peripheral, and auto-
nomic nervous systems [2]. AAAS is an autosomal recessive disorder, due to mutations in the AAAS gene 
(Achalasia, Adrenal insufficiency, Alacrima Syndrome gene) mapping on chromosome 12q13 [3]. The path-
ogenic gene for Triple-A syndrome, AAAS consists of 16 exons, which encode the protein ALA-
DIN(ALacrima Achalasia aDrenal Insufficiency Neurologic disorder) [4]. Mutations in patients with triple A 
syndrome are distributed through all 16 exons of the gene [5, 6]. In addition, pathogenic mutations have been 
reported in introns 4, 5, 11 and 14 [7]. Mutations include point, frame‑shift and nonsense mutations, as well 
as DNA fragment deletions. Although no specific recognition of prominent hot‑spot mutations has been 
found, there appears to be a relatively high frequency of mutations at the following loci: Exon 1 (c.43C>A, 
p. Gly14ValfsX45), exon 8 (c.787T>C, p.Ser263Pro) and intron 14 (c.1331+1G>A, IVS14+1G>A) [5–8] . 
Noteworthy, little correlation has been found among the genotype, phenotype and variable clinical expres-
sion of family members with AAAS [6]. 
ALADIN is a 60-kDa protein with a central ≈170-aa domain composed of four WD repeats. The flanking N 
and C termini, of ≈150 and 230 residues, respectively, contain no obvious structural domains. ALADIN has 
been shown to localize to nuclear pore complexes (NPC), a large multiprotein complex that is central for nu-
cleocytoplasmic transport [3, 9, 10]. Accordingly, ALADIN mutations cause defects in the nuclear import of 
DNA repair proteins and ferritin during interphase [11–14]. Recent studies in human cells have uncovered 
ALADIN’s role in spindle assembly via the spatial regulation of Aurora A kinase [15]. Moreover it was re-
ported that ALADIN is essential for proper meiotic spindle assembly and positioning during meiosis in 
mouse oocytes, leading to severe failures in the first meiotic divisions for most oocytes [15]. 
There is no obvious correlation between different ALADIN mutations and disease phenotype. Patients with 
the same mutation, even patients within the same family, frequently display a high degree of variability in 
the clinical severity and age of onset of their symptoms [16, 17]. This indicates that other factors play an im-
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portant role in the pathogenesis of AAAS.  
In this study, we present a miniseries of three patients with clinical diagnosis of AAAS, who came to our at-
tention from 2006 to 2017. All but one patient presented with an adrenal crisis. Subsequent investigation 
demonstrated the association with other typical features of AAAS, which led us to come to the final diagno-
sis, confirmed by a specific genetic analysis of the AAAS gene. In particular, here we report the identification 
of two novel allelic variants in the ALADIN gene, the frameshift substitution c.765 dupT (p.Gly256Trp 
fsX67) in exon 8 and the splice-site mutation in intron 11 (c.997-2 A>G, IVS11-2A>G). For the majority of 
intronic variations, the consequences on mRNA splicing have been only inferred by in silico analysis, 
whereas here we analyzed the effect of IVS11-2A>G mutation on the splicing process in silico and in vivo. 
Moreover, since we assessed that both mutations identified in this study lead to the formation of a truncated 
protein, we analyzed the expression and subcellular localization of the two novel allelic variants in a cellular 
environment. 
Materials and Methods 
Mutation detection 
The study, accomplishing the Declaration of Helsinki, was approved by Ethic Committee of the Istituto 
Auxologico Italiano, and all patients or their tutors gave a written informed consent. Genomic DNA of the 
probands and their parents was extracted from 3mL of whole blood with Puregene DNA Purification Kit 
(GENTRA Systems) according to the manufacturer recommendations and stored at –20°C until use. The 16 
exons and the flanking intronic regions of the AAAS gene (OMIM 605378) were tested for mutations by se-
quence analysis. PCR amplification of the 16 AAAS fragments was performed using a specific primer sets 
(available upon request). All primers were ordered from Eurofins (Ebersberg, Germany). 
Each PCR product was checked on a 2% agarose gel TAE 1X and purified with GFX™ PCR DNA/Gel Band 
Purification Kit (GE Healthcare IL, United States). the PCR product were sequenced using a Big-Dye Ter-
minator v3.1 cycle sequencing kit (Applied Biosystem Waltham, MA, USA) according to the manufacturer’s 
recommendations and after purification with CENTRI-SEP Spin Columns (Princeton Separations, Freehold, 
NJ, USA) was processed by an ABI-PRISM 3100 automated sequencer (Applied Biosystem Waltham, MA, 
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USA). Sequences with DNA variations were confirmed on a different DNA aliquot.  
RNA Extraction and Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) 
The impact of c.997-2 A>G (IVS11-2A>G) splice site mutations was assessed by RT-PCR analysis of pe-
ripheral blood leukocytes RNAs obtained from patients and parents. Total RNA was isolated from blood col-
lected into ABI Tempus™, by using a Tempus Spin RNA Isolation Kit (Applied Biosystems) according to 
manufacturer instructions. Reverse transcription of total RNA was performed with SuperScript II™ Reverse 
Transcriptase (Invitrogen) according to the manufacturer’s recommendations. Nucleic acids were quantified 
using the Implen Nanophotometer™ Pearl spectrophotometer. The impact of the IVS11-2A>G variant on the 
correct splicing was evaluated for patients and parents by PCR amplification, using specific primers (availa-
ble upon request). 
Real-time quantitative PCR (qPCR) 
Total RNA concentration was spectrofotometrically quantified, and structural integrity of the RNA samples 
was confirmed by electrophoresis in 1% Tris-borate-EDTA (TBE)-agarose gels. After digestion with DNAse 
I (Sigma-Aldrich, Italy), 2 µg of total RNA were retro-transcribed to cDNA via SuperScript II Reverse Tran-
scriptase (Life Thecnologies, Italy). Real-time qPCR assays were performed in a 25 μl reaction volume con-
taining 12.5 μl 2× SYBR Green I PCR Master Mix (Applied Biosystems, USA), 50 ng of cDNA, 10 µM 
forward and reverse primers. Reactions were performed in 96-well µultraAmp PCR Plates—FastPlate96 
(Sorenson) using the ABI Prism 7900 high-throughput sequence detection systems (Applied Biosystems) and 
data were processed by the associated SDS software version 2.3 (Applied Biosystems). 
For each gene an amplification curve was made to evaluate the amplification efficiency. The sequences of 
forward and reverse primers are: AAAS_Ex8_Ex9F forward primer 5′-atgctgctatccgggtatgg-3′ and 
AAAS_Ex12_Ex13 reverse primer 5′-cccaagcctctcctcacc-3′; GAPDH: forward primer 5′-
gggaagcttgtcatcaatgga-3′ and reverse primer 5′-cgccccacttgattttgg-3′. After each PCR, a melting curve was 
always made, to check for specificity of PCR. 
Construction of mutant cDNA expression vectors 
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Plasmid pEGFP-C1 with full length cDNA of AAAS (pEGFP-C1_AAAS_wt) was a generous gift from Pro-
fessor Sungjoo Kim Yoon (Catholic University of Korea) [18][Tissue-specific expression and subcellular lo-
calization of ALADIN, the absence of which causes human triple A syndrome; [A-Ri Cho et al 2009 ]. The 
pEGFP-C1_AAAS_wt vector was used as template to introduce the two variations c.997-2 A>G (IVS11-
2A>G) and c.765dupT (p.Gly256Trp fsX67). The c.765dupT variant was performed by QuikChange Site-
Directed Mutagenesis Kit ( Stratagene; La Jolla, CA, USA) according to the manufacturer’s instruction using 
specific oligonucleotides (FW:cagttggggggcggctgctctcagcttcacccgtggatgc and REV: 
agccgccccccaactgggggcccaggccaagctggtaacagg) . For C.997-2 A>G variant an adapted “Two-stage PCR pro-
tocol” was used [19]. In stage one, two extension reactions were performed in separate tubes; one containing 
the FW1 forward primer and the other containing theREV2 reverse primer. Subsequently, the two reactions 
were mixed, and the standard PCR cloning procedure was carried out on the mixture. The following combi-
nation of oligonucleotides was used: Stage one-FW1 (gcttcgaattccatgtgctctctgg) + REV1 (agcagccag-
tctggggtcagggagcaaaaggcaggagaaggtatgtctgacagcgc) and FW2 (GCGCTGTCAGacataccttctcctgcctttt-
gctccctgaccccagACTGGCTGCT) + REV2 (ggcccgcggttagaggtgggaat). Stage two_FW1+REV2. In both cas-
es Pfu Turbo (Agilent) was used. Restriction enzymes used in the process were EcoRI and SacII from New 
England Biolabs (Beverly, MA, USA).  
Cells and Transfection 
HeLa cells were maintained in DMEM High Glucose medium supplemented with 10% V/V of fetal bovine 
serum (FBS) and 1% of Penicillin:Streptomycin in an incubator at 37°C and 5% of CO2. Twenty-four hours 
before transfection HeLa cells were plated at a density of 1.5×105 on sterile coverslips placed in 35mm Petri 
dishes or on 35 mm Petri dishes and transfected with 2µg of the plasmid constructs using Lipofectamine® 
(Invitrogen) according to the manufacturer instructions. All experiments on HeLa cells were performed 24-
48 hours after transfection. 
Immunocytochemistry 
Twenty-four hours after transfection, cells were washed with PBS, fixed with PBS containing 2% paraform-
aldehyde (Sigma-Aldrich St. Louis, MO, USA) for 15 min at room temperature and rinsed twice with PBS. 
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Permeabilized with 0.1% Triton in PBS for 15 minutes at RT. Blocked with 2% goat serum in PBS for 30 
minutes at room temperature. Incubation happened overnight at 4°C with primary Anti-Nuclear Pore Com-
plex Proteins antibody mAb414 (ab50008, ABCAM) diluted 1:200 in PBS/Goat serum. After four washes 
with PBS, incubation with F(ab')2-Goat anti-Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa 
Fluor 555 (Invitrogen) diluted 1:500 in PBS/Goat serum happened for 1h at room temperature. Cells were 
mounted with ProLong Gold Antifade Mountant with DAPI (Life Technologies, Carlsbad, CA, USA). Imag-
es were acquired by using a laser scanning confocal system installed on a Nikon Eclipse Ti microscope with 
a 60X oil immersion objective.  
Western blot 
Twenty-four hours after transfection, HeLa cells were washed with PBS and suspended in 200 µl of RIPA 
Buffer (10 mM Tris-HCl pH 7,2, 150 mM NaCl, 0,1% SDS, 1.% Triton X-100, 1% sodium deoxycholate, 5 
mM EDTA) supplemented with protease inhibitors left 5 min at RT. Homogenates were centrifuged at 8000 
rpm for 10 min at 4 °C to remove cell debris. Protein content was assayed by the BCA protein Assay Kit 
(Pierce, Rockford, IL 61101 USA). Total proteins were fractionated by SDS electrophoresis on NuPage 4-12 
% Bis-Tris gel (Life Technologies). The iBlot® Transfer Stacks were used to transfer proteins using the 
iBlot® Gel Transfer Device (Invitrogen). After blocking with TBS supplemented with 5% non-fat dry milk 
and 0.1% Tween 20 for 1 hour at RT, membranes were incubated overnight at 4 °C with mouse mAb anti-
GFP (Roche) diluted 1:2000 in TBS-T or anti-Actin (Santa Cruz Biotechnology sc-25778) diluted 1:2000 in 
TBS-T as internal control. After four washings in TBS-T solution 10 minutes each, membranes were incu-
bated for 1 h at room temperature with a 1:4000 dilution of peroxidase-coupled goat anti-mouse antibody. 
Antibody-protein complexes were then detected using the Novex ECL Chemiluminescent substrate or Lumi-
nata Forte Western HRP substrate (Merck KGaA Darmstadt Germany) reagent kit (Life Technologies, 
Carlsbad, CA, USA) followed by autoradiography. 
Results  
Case no 1:  
A Caucasian girl, born from unrelated unaffected parents originating from Sardinia, 
8 
 
 
years with fatigue and hyperpigmented skin. Her physical examination was unremarkable with normal 
growth (height and weight at 87th percentile; target height at 97th percentile). The neurological examination 
evidenced clumsy gait. Endocrine studies confirmed adrenal insufficiency (serum cortisol=9 mcg/L, refer-
ence range 50-250 mcg/L; adrenocorticotropin, ACTH=563 pg/ml, reference range 0-46 pg/mL) and normal 
serum aldosterone (aldosterone 14.7 pg/ml, reference range 10-160 pg/ml) with normal electrolytes. Gluco-
corticoid replacement therapy was then promptly started (hydrocortisone, 12mg per day). Diagnosis of 
AAAS was made later at age 15, when she presented other specific features. Indeed, muscle weakness, hy-
perreflexia and ataxia were also noticed and the electromyoneurography demonstrating motor-sensitive pol-
yneuropathy. Furthermore, alacrimia was diagnosed by Schirmer test. Finally, during follow-up (at the age of 
18 years old), she developed feeding difficulties that led to the following diagnosis of achalasia through a 
specific esophagography. Moreover, at the age of 20 years the patient develops autonomic dysfunctions con-
sisting of occasional dizziness due to orthostatic hypotension and neurogenic bladder which led to recurrent 
urinary tract infections (Table 1). 
The genetic analysis of the AAAS gene was then performed and a compound heterozygosity for previously 
known AAAS mutations c.43C>A (Gly14ValfsX45)/c.1331+1G>A (IVS14+1G>A) [3, 5, 20] was detected. 
Case no. 2 
A Caucasian boy, born from unrelated unaffected parents both with Sardinian origins, presented at 14 years 
because of important weight loss (BMI=14kg/m2) and fatigue. At that age he has no signs of adrenarche 
and/or pubertal development. He had been diagnosed with achalasia one year earlier. Past history revealed 
congenital twisted feet and dysphagia since his 4-6 months of age. On clinical examination, cutaneous-
mucosal hyperpigmentation, muscle weakness and nasal speech were noted. The laboratory examination 
showed normal blood electrolyte as well as liver and kidney function; however, primary adrenal insufficien-
cy was confirmed by the markedly elevated ACTH levels and low serum cortisol (serum cortisol =12 mcg/L, 
reference range 50-250 mcg/L; ACTH>1250 pg/ml, reference range 0-46 pg/mL). Serum aldosterone was 
normal (aldosterone 47pg/ml, reference range 10-160pg/ml). Elettromyoneurography demonstrated axonal 
polyneuropathy and Schirmer test was indicative for alacrimia. Glucocorticoid therapy was then immediately 
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started (Table 1). Patient enters a regular pubertal development 1 year later. Genetic analysis for the AAAS 
gene was then promptly performed. This analysis confirmed the clinical diagnosis of AAAS revealing a nov-
el homozygous substitution in the splice acceptor site (SAS) of intron 11 (c.997-2 A>G, IVS11-2A>G) of the 
AAAS gene. Both parents were heterozygous for the same allelic variant (Figure 1). 
Case no. 3 
A Caucasian girl, first child of non-consanguineous unaffected parents, presented at the age of 4 years old 
with loss of consciousness. Clinical examination, including hormone profile, confirmed the presence of an 
adrenal insufficiency (serum cortisol =10 mcg/l, reference range 50-250 mcg/L; ACTH >1250 pg/ml, refer-
ence range 0-46 pg/mL). Glucocorticoid therapy was then promptly started. Two years later, at the age of 6 
years old, she presented with persistent vomiting. Esophagography demonstrated the presence of megae-
sophagus caused by achalasia. She thus underwent to Heller myotomy followed by Nissen fundoplication. 
She was therefore been asked about the possible presence of combined alacrimia, that she confirmed since 
the birth. Schirmer test was indeed indicative for alacrimia and the final diagnosis of AAAS has been 
reached (Table 1). The indication for the genetic analysis was then evident and revealed a compound hetero-
zygosity for the previously known mutation c.43C>A (p.Gly14ValfsX45) in exon 1 [5, 20] and the novel 
frameshift mutation c.765 dupT (p.Gly256Trp fsX67) in exon 8 of AAAS gene. 
Molecular analysis of the splicing site substitution IVS11-2A>G: 
The sequencing analysis of exon 10-intron 11 PCR product of the AAAS gene of the case no.2 (Figure 2) re-
vealed the splicing site mutation c.997-2 A>G, IVS11-2A>G in the homozygous state. This variation touches 
the splicing acceptor site of exon 11 and has not been previously reported in the scientific literature. The 
Human Splicing Finder (HSF) prediction software [21] predicted that the wild-type acceptor site was modi-
fied suggesting the abolition of the broken wild-type site and the creation of a new cryptic splicing acceptor 
site (Table 2) with the final insertion of a 36 bp intronic sequence. Indeed RT-PCR analysis performed on 
blood samples showed a single band in the normal subject at the expected size of 382bp, whereas a higher 
band was present in the proband (Figure 2). The purification and sequencing of the cDNA band of the patient 
confirm HSF prediction with the insertion of an intronic sequence of 36 bp which determine the introduction 
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of 9 unrelated amino acids and a premature termination codon (PTC) after exon 10 (Figure 2). 
Since this mutation at the splicing acceptor site is expected to generate a truncated protein, we hypothesize 
that the nonsense-mediated mRNA decay (NMD) is triggered. This prompted us to analyze NMD in proband 
and heterozygous carriers (parents), measuring the expression levels of ALADIN transcript. Our findings re-
vealed a highly reduced expression of the mutated allele as an expected result of the activation of the NMD 
process (Figure 3A). Though the expression of the mutated allele was very low and the mutation was pre-
dicted to generate a truncated protein, the mutated and non-mutated molecules shared the first 332 amino ac-
ids, including four WD repeat responsible of the assembly of macromolecular complexes [22]. This made us 
wonder if the mutated protein could conserve in part the ability to localize to NPCs, where it could exert par-
tially its function. The same consideration must be done also for the novel frameshift mutation in exon 8 
(c.765 dupT- p.Gly256Trp fsX67) that leads to a truncated protein partially preserving (until amino acid 255) 
the N terminal portion of ALADIN protein. 
Subcellular localization of naturally occurring truncating mutations 
The C-terminal portion of ALADIN was reported to be crucial for the function of the protein itself [3, 9, 16, 
17, 23–25], indeed numerous mutations identified in AAAS patients result in truncation of this domain. 
Thus, we analyzed the expression and subcellular localization of the two novel allelic variants IVS11-2A>G 
and c.765 dupT identified in our patients; since both mutations resulted in a protein deprived of the C-
terminal domain. Even if the two mutant proteins are expressed in Hela cells (Figure 3B), we observe quali-
tative alterations in their subcellular localization. 
After transfection of GFP-ALADIN and mutant vectors, the GFP-ALADINR332fs (c.997-2 A>G) no longer 
localizes to NPCs but is found predominantly in the cytoplasm (Figure 4B; compare with wild-type localiza-
tion in Figure 4A). Similar results were obtained also with the GFP-ALADING256fs (c.765 dupT) mutant 
(Figure 4C).  
4. Discussion 
AAAS is a rare autosomal recessive congenital disease characterized by adrenal insufficiency (Addison's 
disease), failure of the lower esophageal sphincter to relax (achalasia) and an absence of tear secretion (alac-
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rima). In addition to the three specific features (achalasia, Addison's disease, and alacrimia), AAAS patients 
can develop muscle weakness and neurological abnormalities consisting of autonomic, sensory and motor 
neuropathies. The neurological manifestations has more commonly been reported in older individuals, but 
they can be detected at an early age [26] and can worsen over time.  
The AAAS diagnosis is difficult because of its rarity (the prevalence of disease is unknown) and clinical on-
set heterogeneity. Being AAAS a multisystem and progressive disease, the diagnosis could be delayed, due 
to the long latency observed between the first and the others known signs of the pathognomonic triad [27]. 
Consistently, in the present study we report three novel patients whose final diagnosis of AAAS was 
achieved after a variable period from the first clinical manifestation. Notably, in patient no.1 and no.2 , la-
tency between the earliest clinical feature and final diagnosis of AAAS was more than10 years (Table1). In 
particular, while patient 2 showed axonal polyneuropathy at 14 years old and patient 3 is so far free of symp-
toms, patients 1 showed first neurological signs already at diagnosis (age 3.9 years) with their worsening in 
the young adulthood (age 20 years). It is worth to underline that the regular follow up of this patient allowed 
the early diagnosis and correct management of new manifestations. Thus, our data in according with litera-
ture suggest that neurological abnormalities should be controlled life-long in patients with a confirmed ge-
netic cause. 
Genetic analysis confirmed AAAS diagnosis revealing the presence of two previously described 
(c.43C>A(p.Gln15LyS)/ c.1331+1G>A (IVS14+1G>A) mutations in exon 1 and intron 14 and, most im-
portantly, two novel variants in the AAAS gene, resulting in truncated non-functional proteins (Figure 1). 
Two of our cases (no.1 and no.3) were presenting a partial genotype identity (c. 43C>A, p.Gly14ValfsX45) 
but a quite different phenotype presentation/progression and complexity with a more acute and severe of Ad-
dison's disease presentation in case no. 3 (adrenal crisis with loss of consciousness); on the other hand the 
neurological degenerative features, found in patient no. 1, are the main prognostic factor in AAAS patients, 
once the hormonal defect has been replaced [7, 8]. These differences might be related to the second hetero-
zygous allelic variant but could also confirm the known absence of genotype-phenotype correlation for the 
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AAAS gene allelic variants [9]. No one of our patients showed a mineralocorticoid defect, described in 15% 
of AAAS patients [28, 29]. 
The c.765 dupT (p.Gly256Trp fsX67) in exon 8, a region that has been associated with a high frequency of 
mutations, is a frameshift mutation not reported previously. This mutation results in the substitution of Gly-
cine at amino acid position 256 by Tryptophan leading to the insertion of 67 amino acids alternative to Ala-
din sequence and followed by a premature termination codon (PTC) . Further evaluation revealed that this 
truncated mutant no longer localizes to NPCs but is found predominantly in the cytoplasm (Figure 4B), like-
ly associated with the loss of nucleocytoplasmic transport activity. 
The novel splice site mutation c.997-2 A>G (IVS11-2A>G) turns the A at position c.997-2 into G, losing the 
consensus splice acceptor site (SAS) but creating a new (SAS) upstream in the intron 10, as in silico analysis 
predicted and mRNA analysis demonstrated (Figure 2). The use of the novel splicing site leads to the inser-
tion of an intronic sequence of 36 bp which cause the introduction of 9 amino acids non related with ALA-
DIN protein followed by a PTC after exon 10. This mutation at the SAS was predicted to trigger the non-
sense-mediated mRNA decay (NMD). NMD is a surveillance pathway, whose main function is to reduce er-
rors in gene expression by abolishing mRNA transcripts that contain premature termination codons. This 
prevents the translation of aberrant transcripts and limits the synthesis of abnormal proteins [30], such as the 
transcripts generated from the mutated allele. This prompted us to analyze NMD in proband and heterozy-
gous carrier (father), determining the expression levels of ALADIN transcript. Our findings revealed a sig-
nificant reduction of the mutated allele expression as an expected result of the activation of the NMD process 
(Figure 3A). Even if the expression of the mutated allele was low and the mutation at the (SAS) sequence 
was predicted to generate a truncated protein, the mutated and non-mutated proteins shared the first 332 ami-
no acids, including four WD repeat responsible of the assembly of macromolecular complexes [22]. Thus, 
we analyzed the expression and subcellular localization of this novel allelic variant (IVS11-2A>G). Even if 
the GFP-ALADIN mutant expression is partially conserved after overexpression in Hela cells (Figure 3B), 
we observe qualitative differences in its subcellular localization. In particular we observe that the mutated 
protein is found predominantly in the cytoplasm. Similar results were obtained with several other pathogenic 
13 
 
 
ALADIN mutations that disrupt larger stretches of the C terminus. Almost all known nonsense, frameshift, 
and splice-site mutations that encode for an ALADIN protein lacking this domain will not localize to NPCs. 
Our findings confirm that the C-terminal domain of ALADIN is essential for its correct targeting to NPCs 
(Figure 4). Besides, the observation that this domain is deleted in a large number of AAAS patients point out 
that NPC targeting is essential for normal ALADIN function [20, 31]. 
In conclusion, we report two novel variants in the AAAS gene, both resulting in a truncated non-functional 
ALADIN protein. No clear-cut genotype-phenotype correlation could be deduced from our study, a lack of 
which has been seen in other studies as well [32][33]. Nonetheless, our findings highlight the essential role 
of the C terminal domain of the protein for its correct targeting and function and underline the importance of 
sequencing splice sites surrounding the intron-exon junctions and the need to carry out additional RNA stud-
ies to ensure precise molecular diagnosis and correct genetic counseling. 
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Figure Legend 
Figure 1. Family pedigree and detection of the c.992-2A>G and c.765dup T mutations 
Pedigree of the two families. Direct sequence analysis of the AAAS gene identified the two novel mutations 
of AAAS gene c.997-2A>G and c.765dup T. 
Figure 2. Sequencing representation of the cDNA analysis 
(A) Gel electrophoresis of the RT-PCR amplification. MW = 50bp DNA Step Ladder ( Promega); WT = 
normal; P = patient; (B) chromatogram and schematic representation of the mutated allele, including exon 
10, part of intron 10 and exon 11. The RED BOX indicates the STOP GAIN. 
Figure 3. Nonsense pre-mRNA mediated decay analysis. (A) mRNA expression of AAAS WT (CTRL) 
and mutated allele (PROBAND) by qPCR performed on blood samples. GAPDH mRNA was used to nor-
malize template levels. Values are mean ± SEM and represent the relative expression compared with controls 
(AAAS/GAPDH mRNA levels). qPCR experiments were performed in triplicate wells for each subject and 
repeated on two different aliquot of blood . (B) Western blot analysis of Hela cells expressing the wild-type 
GFP-ALADIN (1) ,the GFP-ALADINR332fs (c.997-2 A>G) (2) variant or GFP-ALADING256fs (c.765 
dupT) (3) variant. Cells transfected with the empty vector (GFP alone) were loaded as control (4). While in 
the GFP-ALADIN an accumulation of a main band with molecular masses of 90-100 kDa was observed, in 
the mutated proteins we observed a lower molecular mass signal, as expected for truncated proteins. Anti-
actin antibody was used as internal loading control. The presence of higher molecular weight faint bands for 
WT and mutated proteins is possibly due to the GFP tag, as higher bands (>27 kDa) were present also in the 
cells transfected with GFP protein only. 
Fig. 4. The C-terminal domain of ALADIN is essential for NPC targeting. The localization of GFP-
tagged ALADIN constructs is shown on the right of each image (green). (A) Wild-type ALADIN. (B) 
ALADING256fs variant (C) the ALADINR332fs variant. The localization of NPCs is shown on the middle 
of each image (red) by immunostaining with mAb414 (recognizes Nup358, Nup214, Nup153, and Nup62). 
The merged signal is shown on the left of each image. 
 
Table 1. Clinical summary of the patients. 
 
Legend: AI=adrenal insufficiency; AL= alacrimia; AC: achalasia/swallowing difficulties; HR= 
hyperreflexia; MW: muscle weakness; NS= nasal speech; AT= ataxia/clumsiness; PN= polyneuropathy; 
AN=autonomic neuropathy; a Number in parentheses indicates age when the AAAS symptoms appeared. 
 
Patient Sex 
Age 
at 
onset 
(yr) 
Complaints 
on 1st 
admission 
Age at 
definitive 
TAS 
diagnosis 
(year) 
AI 
(yr)a 
AL 
(yr)a 
AC 
(yr)a 
HR 
(yr)a 
MW 
(yr)a 
NS 
(yr)a 
AT 
(yr)a 
PN 
(yr)a 
AN 
(yr)a 
AAAS gene allelic 
variant 
1 F 3.9 
fatigue and 
hyper-
pigmented 
skin 
15 + (3.9) 
+ 
(15) 
+ 
(18) 
+ 
(15) 
+ 
(15) 
+ 
(12) 
+ 
(15) 
+ 
(15) 
+ 
(20) 
c.43C>A 
(p.Gly14ValfsX45) 
c.1331+1G>A 
(IVS14+1 G>A) 
2 M 0.6 weight loss and fatigue 14 
+ 
(14) 
+ 
(14) 
+ 
(0.6) 
+ 
(14) 
+ 
(14) 
+ 
(14) 
+ 
(14) 
+ 
(14) - 
c.997-2 A>G, 
(IVS11-2A>G) 
 
3 F 4 loss of consciousness 6 
+ 
(4) 
+ 
(6) 
+ 
(6) 
+ 
(6) 
+ 
(6) 
+ 
(6) 
+ 
(6) - - 
c.43C>A 
(p.Gly14ValfsX45) 
c.765 dupT 
(p.Gly256TrpfsX67) 
Table 2. HSF prediction of the c.997-2A>G mutation on the splicing (http://www.umd.be/HSF3/index.html) 
 
 
 
 
cDNA 
Position 
Splice 
Site type Motif 
New splice 
site 
Wild 
Type Mutant 
Variation 
(%) 
c.997-12 Acceptor ccctgaccccagAC ccctgaccccggAC 86.21 57.26 
WT site 
broken 
-33.58 
c.997-48 Acceptor attctactatagac attctactatagAC 80.07 80.07 New splicing site 




